Literature DB >> 15090718

International trends in prostate-cancer mortality: the decrease is continuing and spreading.

P D Baade1, M D Coory, J F Aitken.   

Abstract

OBJECTIVE: To measure recent changes in prostate-cancer mortality across 24 developed countries.
METHODS: Mortality data for men aged 50-79 years were obtained from the World Health Organisation mortality database and we assessed trends in age-standardised mortality rates using joinpoint regression models.
RESULTS: Significant reductions in prostate-cancer mortality were observed in United Kingdom, United States, Austria, Canada, Italy, France, Germany, Australia and Spain, and downward trends were also observable in the Netherlands, Ireland and Sweden.
CONCLUSIONS: Mortality declines for prostate cancer are now evident in 12 out of the 24 developed countries considered in this analysis. Increases in PSA screening and better treatment of early-stage disease, possibly acting in combination, remain plausible hypotheses. Copyright 2004 Kluwer Academic Publishers

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090718     DOI: 10.1023/B:CACO.0000024212.66334.26

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  14 in total

1.  Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

Review 2.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

3.  Report on trends of incidence (1970-2002) of and mortality (1952-2002) from cancer in Germany.

Authors:  Nikolaus Becker; Hans-Peter Altenburg; Christa Stegmaier; Hartwig Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-03       Impact factor: 4.553

4.  Engineering of human coagulation factor x variants activated by prostate-specific antigen.

Authors:  Tina Völkel; Hans-Heinrich Heidtmann; Rolf Müller; Roland E Kontermann
Journal:  Mol Biotechnol       Date:  2005-01       Impact factor: 2.695

5.  Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Authors:  Weisheng Zhang; Brian B Haines; Clay Efferson; Joe Zhu; Chris Ware; Kaiko Kunii; Jennifer Tammam; Minilik Angagaw; Marlene C Hinton; Heike Keilhack; Cloud P Paweletz; Theresa Zhang; Chris Winter; Sriram Sathyanarayanan; Jonathan Cheng; Leigh Zawel; Stephen Fawell; Gary Gilliland; Pradip K Majumder
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

6.  Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.

Authors:  N M Corcoran; C M Hovens; M Michael; M A Rosenthal; A J Costello
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

7.  [Epidemiology of prostate cancer: recent results from the Epidemiological Cancer Register of the District of Münster (Germany)].

Authors:  K Kraywinkel; M Lehnert; A Semjonow; H-W Hense
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

8.  Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma.

Authors:  Hakan Soylu; Nuray Acar; Ozlem Ozbey; Betul Unal; Ismail Turker Koksal; Ibrahim Bassorgun; Akif Ciftcioglu; Ismail Ustunel
Journal:  Pathol Oncol Res       Date:  2015-09-05       Impact factor: 3.201

Review 9.  Castration-resistant prostate cancer: systemic therapy in 2012.

Authors:  Fernando C Maluf; Oren Smaletz; Daniel Herchenhorn
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

10.  Incidence, mortality and survival patterns of prostate cancer among residents in Singapore from 1968 to 2002.

Authors:  Sin Eng Chia; Chuen Seng Tan; Gek Hsiang Lim; Xueling Sim; Yudi Pawitan; Marie Reilly; Safiyya Mohamed Ali; Weber Lau; Kee Seng Chia
Journal:  BMC Cancer       Date:  2008-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.